Article in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Ting-Syuan LinWarshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China.ORCID 0000-0002-7274-4100
Jingting WanWarshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China.
Jingjin HeDepartment of General Practice, Shenzhen Luohu People's Hospital, Shenzhen 518000, China.ORCID 0000-0001-6848-8071
Shidong CuiWarshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China.
Yun HuangDepartment of General Practice, Shenzhen Luohu People's Hospital, Shenzhen 518000, China.
Bojian ZhangWarshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China.
Hsi-Yuan HuangWarshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China.ORCID 0000-0001-8453-4939
Kexin ZhuWarshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China.
Jihang ChenWarshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China.
Tao ZhangBetter Way Group-Chinese University of Hong Kong (Shenzhen) Warshel Joint Laboratory for Skin Health and Active Molecule Innovation, Shenzhen 518172, China.ORCID 0009-0007-5655-3287
Shangfu LiWarshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China.
Liao HuDepartment of Electrical & Computer Engineering, University of Illinois at Chicago, Chicago, IL 60607, USA.ORCID 0009-0002-7147-8581
Yongfei WangWarshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China.ORCID 0000-0002-1260-6291
Hsien-Da HuangWarshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China.
Ping TangDepartment of General Practice, Shenzhen Luohu People's Hospital, Shenzhen 518000, China.ORCID 0000-0002-7964-8074
Yang-Chi-Dung LinWarshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China.ORCID 0000-0003-2436-4602
Funding
2023 The Second Affiliated Hospital of the Chinese University of Hong Kong, Shenzhen Joint Fund Project HUUF-MS-202308, HUUF-MS-202309Better Way Group - Chinese University of Hong Kong (Shenzhen) Warshel Joint Laboratory for skin health and active molecule innovation 2024E0087CUHK(SZ) GeneBioHealth Advanced Molecular Diagnostics Laboratory 2024E0088CUHK(SZ) HOMEY HEALTH Microbiome and EndoMetabolic Digital Health Research Center 2024E0049General project of Guangdong Provincial Basic and Applied Basic Research Foundation Natural Science Foundation 2022A1515011381Guangdong Science and Technology Program 2024A0505050001, 2024A0505050002Guangdong Young Scholar Development Fund of Shenzhen Ganghong Group Co., Ltd. 2021E0005, 2022E0035National Natural Science Foundation of China 32070674Phase III Government Matching Fund of Shenzhen Ganghong Group Co., Ltd. 2023E0012Shenzhen-Hong Kong Cooperation Zone for Technology and Innovation HZQB-KCZYB-2020056, P2-2022-HDH-001-AShenzhen Key Medical Discipline Construction Fund SZXK062Shenzhen Science and Technology Program JCYJ20220530143615035Shenzhen Science and Technology Program JCYJ20250604141041017The Shenzhen-Hong Kong Jointly Funded Project SGDX20230116093201002Warshel Institute for Computational Biology funding from Shenzhen City and Longgang District LGKCSDPT2025001
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Arecoline as a Novel Scaffold Targeting the ATAD2 Bromodomain for Cell Cycle Modulation. · full record | OpenQuestion